(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/193896 A3

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
A61P 3/04 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/US2025/019688

(22) International Filing Date:
13 March 2025 (13.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/566,017 15 March 2024 (15.03.2024) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **AI, Minrong**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US). **CHILTON, Todd C.**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US). **BRIERE, Daniel A.**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US). **CAIN, Paul F.**; c/o Eli Lilly and Company, PO Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **WOO, Perry** et al.; ELI LILLY AND COMPANY, PO Box 6288, Indianapolis, Indiana 46285 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
23 October 2025 (23.10.2025)

WO 2025/193896 A3

(54) Title: LEPTIN RECEPTOR AGONISTIC ANTIBODY AS MONO OR COMBO THERAPIES TO TREAT OBESITY

(57) Abstract: Leptin receptor (LEPR) is a single-pass transmembrane receptor that belongs to the cytokine receptor family. The secreted ligand Leptin binds to LEPR and activates intracellular downstream signal cascades. Leptin and LEPR play critical role in body weight regulation. The antibodies of the present disclosure have agonistic activities on LEPR and can therefore be used as therapeutic agents to treat obesity.